Rheumatology
Cohort Study | Mortality risk in anti-MDA5 dermatomyositis linked to rapid ILD progression and anti-Ro52 antibody levels
11 Aug, 2023 | 15:21h | UTC
Commentary on Twitter
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
– rapidly progressive interstitial lung disease
– anti-Ro52 antibody
– age > 57 years
(based on study of 126 MDA-5+ DM pts)https://t.co/JLGIgALUip pic.twitter.com/boTTzrixk9— Dr. John Cush (@RheumNow) August 5, 2023
Cohort Study | Vegetarian diet linked to elevated hip fracture risk; BMI plays a partial role
9 Aug, 2023 | 15:16h | UTC
Systematic review informing the 2022 EULAR recommendations for the management of ANCA-associated vasculitis
7 Aug, 2023 | 14:47h | UTCGuideline: EULAR recommendations for the management of ANCA-associated vasculitis
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
7 Aug, 2023 | 14:45h | UTC
Review | Autoimmunity and postural orthostatic tachycardia syndrome: Implications in diagnosis and management
4 Aug, 2023 | 11:49h | UTC
RCT | Risankizumab outperforms apremilast in moderate plaque psoriasis treatment
3 Aug, 2023 | 13:21h | UTCCommentary: Risankizumab Shown to be Superior to Apremilast in Treating Adults with Moderate Psoriasis – HCP Live
2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease
2 Aug, 2023 | 14:02h | UTCCommentary: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease – RheumNow
RCT | Baricitinib demonstrates efficacy in treatment-resistant juvenile idiopathic arthritis
2 Aug, 2023 | 13:45h | UTCBaricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW in @TheLancet—Baricitinib was efficacious with an acceptable safety profile in patients with #juvenile idiopathic #arthritis in a phase 3 withdrawal trialhttps://t.co/vZyXUwBiDZ #JIA
Plus linked Comment: https://t.co/VWofLvL427 pic.twitter.com/MGVoUz4xIv
— The Lancet Rheumatology (@TheLancetRheum) July 10, 2023
Novel therapeutics for management of lupus nephritis: what is next?
1 Aug, 2023 | 14:22h | UTCNovel Therapeutics for Management of Lupus Nephritis: What Is Next? – Kidney Medicine
Review | First-line immunosuppression in neuromuscular diseases
1 Aug, 2023 | 14:09h | UTCFirst-line immunosuppression in neuromuscular diseases – Practical Neurology
Cohort Study | More data suggests SGLT-2 inhibitors could reduce gout flares
26 Jul, 2023 | 13:24h | UTCComparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries:
SGLT-2 inhibitors reduced gout flares in patients with diabetes, gout – ACP Internist
SGLT2i Use Linked to Reduced Risk for Flare in Adults With Gout, T2D – HealthDay
SGLT2 inhibitors linked with fewer gout flares in diabetes – MDedge
Cohort Study | The role of antiphospholipid syndrome and specific antibodies in predicting SLE pregnancy complications
25 Jul, 2023 | 13:44h | UTCPregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER) – Seminars in Arthritis and Rheumatism (link to abstract – $ for full-text)
Commentary: SLE and Pregnancy Outcomes – RheumNow
M-A | Comparison of systemic treatments for chronic plaque psoriasis – Anti-IL17 stands out
25 Jul, 2023 | 13:27h | UTC
Review | Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA): two sides of the same coin
7 Jul, 2023 | 16:01h | UTCHES and EGPA: Two Sides of the Same Coin – Mayo Clinic Proceedings
RCT | Opioids not more effective than placebo for acute low back and neck pain
5 Jul, 2023 | 01:15h | UTCOpioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
News Releases:
Opioids no more effective than placebo for acute back and neck pain – University of Sidney
Opioid pain relievers do not reduce acute lower back and neck pain, study suggests – The Lancet
Commentary from the authors: Opioids don’t relieve acute low back or neck pain – and can result in worse pain, new study finds – The Conversation
Consensus Statement | Evaluation and management of deficiency of adenosine deaminase 2
30 Jun, 2023 | 14:53h | UTCInvited Commentary: Finding a Quorum in Deficiency of Adenosine Deaminase 2 Management – JAMA Network Open
Podcast | Wisely ordering autoantibodies
28 Jun, 2023 | 13:09h | UTC#399 Wisely Ordering Autoantibodies – ACP IM2023 – The Curbsiders
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis
27 Jun, 2023 | 13:37h | UTC
Commentary on Twitter
Have you checked the latest recommendations? @eular_org points to consider for the definition of clinical and imaging features suspicious for progression from PsO to PsA
▶️ 3 stages relevant to PsA prevention
▶️ 5 OP and 10 points to consider? https://t.co/Kr9akTjNC6 pic.twitter.com/cHsg0ZTlb6
— ARD & RMD Open (@ARD_BMJ) June 21, 2023
RCT | Rituximab and MMF combo improves lung function vs. MMF in interstitial lung disease with NSIP pattern, but may increase infection risk
21 Jun, 2023 | 13:16h | UTCRituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial – European Respiratory Journal (link to abstract – $ for full-text)
Commentary on Twitter
ERJ: Rituximab plus MMF is associated with benefits in lung function and progression-free survival compared with MMF plus placebo after 24 weeks of treatment. The safety profile of rituximab plus MMF was similar to that of MMF plus placebo. https://t.co/Mv0IuzLljz pic.twitter.com/1igrt6uDK4
— ERS publications (@ERSpublications) June 11, 2023
M-A | Biosimilar and reference biologics in rheumatoid arthritis show equivalent results
15 Jun, 2023 | 14:47h | UTCCommentary: Adalimumab, Etanercept, Infliximab Biosimilars Show Clinically Equivalence to Biologics in RA – HCP Live
Review | The cervical spine in tension type headache
13 Jun, 2023 | 13:58h | UTCThe cervical spine in tension type headache – Musculoskeletal Science and Practice
Commentary on Twitter
The cervical spine in tension type headache
???https://t.co/EFcxBlDO34 pic.twitter.com/y7SyA3T7qt
— Physio Meets Science (@PhysioMeScience) June 1, 2023
Cohort Study | Prognostic model for predicting methotrexate toxicity in immune mediated inflammatory diseases
12 Jun, 2023 | 13:26h | UTCNews Release: New study reveals way to predict side-effect risk from common immune suppressant medication – University of Nottingham
Commentary: Prognostic model stratifies risk for methotrexate toxicity – ACP Internist
Exploratory Analysis of a RCT | Low-dose colchicine linked to reduced incidence of knee and hip replacements
7 Jun, 2023 | 13:50h | UTCAssociation of Low-Dose Colchicine With Incidence of Knee and Hip Replacements: Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Low dose colchicine associated with lower incidence of total knee and hip replacements – American College of Physicians
Review | Erythrocyte sedimentation rate and C-reactive protein in the ED
7 Jun, 2023 | 13:47h | UTCErythrocyte Sedimentation Rate and C-Reactive Protein in the ED – emDocs
Systematic Review | Impact of physical therapies on pain, function, and life quality in myofascial pain syndrome
6 Jun, 2023 | 14:07h | UTC